Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190009/S006

OPRA Implant System, Abutment component

Integrum AB · Decision date Nov 20, 2025

FDA DECISIONP190009/S006

What did the FDA approve?

FDA records P190009/S006 as a supplement to PMA P190009, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Nov 20, 2025.

FDA approval order statement

approval of an addition of a Low Plasticity Burnishing (LPB) step in the manufacturing process of the Abutment component of the OPRA device.
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Orthopedic
Decision date
Nov 20, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P190009/S006
Regulatory pathway
PMA supplement
Applicant
Integrum AB
Product code
PJY
Decision code
APPR
Decision date
Nov 20, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Osseoanchored prostheses for the rehabilitation of transfemoral amputees.

Applicant
Integrum AB
Product code
PJY
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190009/S006 received

    Application receipt date recorded by FDA.

  2. P190009/S006 · FDA decision

    135 Review Track For 30-Day Notice

Timeline entries are records held by MedtechLedger for P190009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190009

Product / regulatory recordCompanyPathwayDecision dateSource
Integrum ABPMA supplementAug 14, 2025FDA
Integrum ABPMA supplementFeb 12, 2026FDA
Integrum ABPMA supplementMar 12, 2026FDA
Integrum ABPMA supplementApr 15, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integrum AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Krokslatts Fabriker 50, Mölndal, SE-431 37

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records